References
- Baert, F. J., D’Haens, G. R., Peeters, M., Hiele, M. I., Schaible, T. F., Shealy, D., Geboes, K., Rutgeerts, P. J. (1999). Tumor necrosis factor alpha antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn’s ileocolitis. Gastroenterology, 116 (1), 22–28.10.1016/S0016-5085(99)70224-6
- Best, W. R., Becktel, J. M., Singleton, J. W., Kern Jr., F. (1976). Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology, 70 (3), 439–444.10.1016/S0016-5085(76)80163-1
- Colombel, J., Rutgeerts, P., Sandborn, W. J. (2010). Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn’s disease: Results from EXTEND. J. Crohn’s Colitis, 4, S11. Abstract OP31.
- Colombel, J., Rutgeerts, P., Sandborn, W. J. (2010). Deep remission predicts long-term outcomes for adalimumab-treated patients with Crohn’s disease: Data from EXTEND. Gut, 59 (Suppl. 3), A80. Abstract OP371.
- Das, M., Sundell, I. B., Koka, P. S. (2013). Adult mesenchymal stem cells and their potency in the cellbased therapy. J. Stem Cells, 8 (1), 1–16.
- Duijvestein, M., Molendijk, I., Roelofs, H., Vos, A. C., Verhaar, A. P., Reinders, M. E., Fibbe, W. E., Verspaget, H. W., van den Brink, G. R., Wildenberg, M. E., Hommes, D. W. (2011). Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease. Cytotherapy, 13 (9), 1066–1073.10.3109/14653249.2011.59737921846292
- Froslie, K. F., Jahnsen, J., Moum, B. A. (2007). Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort. Gastroenterology, 133 (2), 412–422.10.1053/j.gastro.2007.05.05117681162
- Huang, H. R., Zan, H., Lin, Y., Zhong, Y. Q. (2014). Effects of azathioprine and infliximab on mesenchymal stem cells derived from the bone marrow of rats in vitro. Mol. Med. Rep., 9 (3), 1005–1012. DOI: 10.3892/mmr.2014.1905.10.3892/mmr.2014.190524435621
- Kaplan, E. I., Meier, P. (1958). Nonparametric estimation from incomplete observations. J. Amer. Stat. Assoc., 53, 457.10.1080/01621459.1958.10501452
- Knyazev, O., Parfenov, A., Shcherbakov, P., Ruchkina, I., Konoplyanikov, A. (2013). Refractory forms of Crohn's disease cell therapy. Cell. Technol. Biol. Med., 3, 145–152.
- Lichtenstein, G. R., Rutgeerts, P. (2010). Importance of mucosal healing in ulcerative colitis. Inflamm. Bowel Dis., 16, 338–346. DOI: 10.1002/ibd.20997.10.1002/ibd.2099719637362
- Najar, M., Raicevic, G., Fayyad-Kazan, H., Bron, D., Toungouz, M., Lagneaux, L. (2016). Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells. Cytotherapy, 18 (2), 160–171. DOI: 10.1016/j.jcyt.2015.10.011.10.1016/j.jcyt.2015.10.01126794710
- Pineton de Chambrun, G., Peyrin-Biroulet, L., Lémann, M., Colombel, J. F. (2010). Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol., 7 (1), 15–29.10.1038/nrgastro.2009.20319949430
- Tsyb, A. F., Konoplyannikov, A. G., Kolesnikov, A. I., Pavlov, V. V. (2004). Preparation and use in medicine, cell cultures of human mesenchymal stem cells of bone marrow cells. Herald of the Russian Academy of Medical Sciences, 59 (9), 71–76.
- Vorobyev, G. I., Khalif, I. L. (2008). Non-specific Inflammatory Bowel Disease. Miklos.
- Watkins, P. E., Warren, B. F., Stephens, S., Ward, P., Foulkes, R. (1997). Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut, 40 (5), 628–633.10.1136/gut.40.5.62810271669203942
- Zallot, C., Peyrin-Biroulet, L. (2013). Deep remission in inflammatory bowel disease: Looking beyond symptoms. Curr. Gastroenterol. Rep., 15 (3), 315. DOI: 10.1007/s11894-013-0315-7.10.1007/s11894-013-0315-723354742